Abstract
Editor's note: The topic of testosterone (T) and prostate cancer is timely and provocative. The Institute of Medicine report on testosterone and aging suggested that knowledge regarding T-replacement therapy in aging men was inadequate, urging a cautious approach to T replacement in this population. The Food and Drug Administration appears to support this cautionary stance. Counter arguments by Rhoden and Morgentaler in the New England Journal of Medicine suggest that T-replacement therapy in aging men may be safe under controlled settings. This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barqawi, A., Crawford, E. Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int J Impot Res 17, 462–463 (2005). https://doi.org/10.1038/sj.ijir.3901323
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901323
This article is cited by
-
Differing levels of testosterone and the prostate: a physiological interplay
Nature Reviews Urology (2011)
-
Testosterone therapy for men at risk for or with history of prostate cancer
Current Treatment Options in Oncology (2006)
